FindTrial
Sign In

Early warning effect of apolipoprotein A5 in the occurrence and prognosis of severe hepatitis

Early warning effect of apolipoprotein A5 in the occurrence and prognosis of severe hepatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-PRCH-13002984
Enrollment
Unknown
Registered
2013-01-08
Start date
2013-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe hepatitis B

Interventions

Mild liver damage group:NA
Severe liver damage group:NA
Liver failure group:NA
Health control group:NA

Sponsors

Center of Infectious Diseases, West China Hosptial of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Chronic hepatitis B patients with different severity of the disease.

Exclusion criteria

Exclusion criteria: 1.HCV or HIV co-infection; 2. Evidence of alcoholic liver disease , autoimmune hepatitisor decompensated cirrhosis; 3. Evidence of defective treatment.

Design outcomes

Primary

MeasureTime frame
ApoA5;—

Contacts

Public ContactChen En-Qiang
chenenqiang1983@hotmail.com+86 15882476562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026